Syndax Pharmaceuticals SNDX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $217.42M+397% | $172.6M+629% | $111.55M+597% | $78.18M+2,134% | $43.72M— | ||
| $255.99M+3.7% | $258.78M+7.1% | $245.67M+6.2% | $260.36M+30.6% | $246.79M+33.1% | ||
| —— | $179.68M+48.6% | $164.98M+53.6% | $150.28M+60.0% | $135.58M+68.6% | ||
| —— | —— | —— | —— | —— | ||
| $440.95M+13.8% | $445.68M+22.7% | $418.45M+24.1% | $417.23M+43.1% | $387.64M+47.1% | ||
| -$223.53M+35.0% | -$273.08M+19.6% | -$306.9M+4.5% | -$339.05M-17.7% | -$343.92M-30.5% | ||
| -102.8%+684pp | -158.2%+1,276pp | -275.1%+1,732pp | -433.7%+7,795pp | -786.6%— | ||
| $4K+107% | $6K+700% | -$118K-163% | -$95K-141% | -$54K-124% | ||
| -$19.72M-255% | -$12.34M-159% | -$4.68M-119% | $4.06M-83.0% | $12.71M-44.3% | ||
| —— | —— | —— | —— | —— | ||
| -$243.25M+26.6% | -$285.42M+10.5% | -$311.58M-4.9% | -$334.99M-26.8% | -$331.2M-37.6% | ||
| -111.9%+646pp | -165.4%+1,181pp | -279.3%+1,577pp | -428.5%+7,117pp | -757.5%— | ||
| -$2.79+27.5% | -$3.29+11.6% | -$3.60+1.1% | -$3.88-14.5% | -$3.85-19.2% | ||
| -$223.53M+35.0% | -$273.08M+19.6% | -$306.9M+4.5% | -$339.05M-17.7% | -$343.92M-30.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Syndax Pharmaceuticals's revenue?
- Syndax Pharmaceuticals (SNDX) generated $217.4M in revenue over the trailing twelve months, up 397.3% year over year.
- Is Syndax Pharmaceuticals profitable?
- Syndax Pharmaceuticals is not currently profitable: it reported a net loss of $243.2M over the trailing twelve months, a -111.9% net margin.
- What is Syndax Pharmaceuticals's earnings per share?
- Syndax Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.79.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
